|Bid||1.1600 x 47300|
|Ask||1.1800 x 3200|
|Day's Range||1.1400 - 1.2000|
|52 Week Range||0.9210 - 29.2500|
|Beta (5Y Monthly)||2.19|
|PE Ratio (TTM)||N/A|
|Earnings Date||Nov 12, 2020|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||0.25|
Inpixon (Nasdaq: INPX), the Indoor Intelligence™ company, today announced that it has entered into a securities purchase agreement with an accredited institutional investor to purchase 8,000,000 shares of common stock (or pre-funded warrants in lieu thereof) and warrants to purchase up to an aggregate of 8,000,000 shares of common stock at a purchase price of $1.25 per share (or $1.249 per prefunded warrant) and accompanying warrant in a registered direct offering with a single institutional investor priced at-the-market under Nasdaq rules. The warrants have an exercise price of $1.25 per share, are exercisable immediately, and will expire five years following the date of issuance.
Inpixon (Nasdaq: INPX), the Indoor Intelligence™ company, today announced that Inpixon Mapping has been selected by one of the world's premier pharmaceutical companies to provide the visualization required for tracking its critical COVID-19 vaccine-related assets. Inpixon Mapping is currently contracted for deployment in multiple facilities utilized by this company, which specializes in the development of medicines and vaccines across a wide range of disciplines, and multiple additional locations are anticipated to be added over the coming weeks and months.
Inpixon (Nasdaq: INPX), the Indoor Intelligence™ company, today provided a business update and reported financial results for the third quarter of 2020.